Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. …

Background Preclinical studies suggest that Reed–Sternberg cells exploit the programmed
death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, …

Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory
to or that relapses after immunochemotherapy and transplantation have a poor prognosis…

Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma
(SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are …

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway
to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur …

Background Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling
and microenvironmental support signals that promote the growth and survival of malignant B …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response …

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell
malignancies, but patients discontinue these agents due to resistance and intolerance. …